Approved indications: In the United States, Metopirone is approved only as part of diagnostic testing to assess adrenal insufficiency in adults and children and is not FDA-approved for long-term treatment of any condition.

Off-label uses: Endocrinologists may prescribe repeated or divided doses of metyrapone off-label to lower cortisol in endogenous Cushing’s syndrome (for example before surgery, while awaiting other treatments, or when other options are not suitable), supported mainly by decades of clinical experience and observational studies showing effective cortisol reduction in many patients.

Efficacy expectations:

• For diagnostic use, Metopirone changes adrenal hormone production within hours, so next-morning blood or urine tests can show whether the pituitary–adrenal system responds normally.
• For off-label Cushing’s treatment, cortisol levels often fall within days of starting or adjusting therapy, with clinical improvements in features such as blood pressure, blood sugar control, and energy over weeks to months when cortisol is kept in the target range.
• Compared with other cortisol-lowering drugs (such as ketoconazole or osilodrostat), metyrapone has similar cortisol-lowering potential but tends to cause more androgen-related effects (acne, oily skin, excess hair growth), so choice of drug is individualized and requires close endocrine follow-up.

Diagnostic dosing (approved use): For adults and children, the standard overnight test uses a single oral dose of 30 mg/kg body weight (up to a maximum of 3,000 mg) taken at midnight with milk, yogurt, or a snack, followed by blood sampling in the early morning exactly as scheduled by the clinician.

Therapeutic dosing (off-label for Cushing’s syndrome): When used off-label to treat endogenous Cushing’s syndrome, endocrinologists typically start with low divided doses (for example 250 mg several times daily) and carefully adjust based on cortisol measurements and clinical response; this is not an FDA-approved indication and should only be done under specialist supervision.

How to take: Swallow capsules whole with food or milk to reduce stomach upset, and follow the exact timing instructions, since the interpretation of test results depends closely on when the dose and blood samples are taken.

Special instructions: Medicines that affect adrenal or pituitary function (such as corticosteroids, certain anticonvulsants, hormone therapies, or antithyroid medicines) are often stopped several days in advance if medically feasible, and patients at high risk for adrenal crisis may be observed in the hospital and sometimes given preventive corticosteroids after testing.

Missed dose: If you miss or vomit the test dose, do not repeat it on your own; contact the ordering clinician for instructions about rescheduling or repeating the test, and for any off-label chronic regimen ask in advance how to handle missed doses.

Overdose: Taking more than prescribed can cause prolonged suppression of adrenal hormones, severe nausea or vomiting, marked drowsiness, or low blood pressure; emergency medical care and consultation with poison control are required if an overdose is suspected.

Common side effects: With single-dose diagnostic testing, common reactions include nausea, vomiting, abdominal discomfort, headache, dizziness, and sleepiness, usually starting within a few hours of the dose and resolving within a short period; most are mild to moderate.

Serious or rare adverse effects:

• Acute adrenal insufficiency (severe weakness, low blood pressure, intense nausea or vomiting, confusion) in people with limited adrenal reserve, which is a medical emergency and requires prompt corticosteroid treatment and monitoring.
• Allergic reactions such as rash, itching, hives, facial swelling, or trouble breathing.
• Rare blood and circulatory problems, including low blood pressure and reduced red or white blood cells or platelets.

Warnings and precautions: Metopirone must not be used in people with known adrenal cortical insufficiency or who are allergic to metyrapone; testing is often done under close supervision in patients with suspected severe adrenal or pituitary disease, serious illness, or in children, and extra caution is used in those who are pregnant, breastfeeding, or who have significant liver or kidney problems.

Safety compared with other drugs: For a one-time diagnostic dose, overall risk is relatively low; with off-label long-term use for Cushing’s syndrome, safety concerns increase and include adrenal insufficiency, high blood pressure, electrolyte changes, and androgen-related side effects, so it is generally reserved for specialist management.

Reporting side effects and updates: Suspected side effects should be reported to a healthcare professional and can also be reported directly to the FDA MedWatch program (online or by calling 1-800-FDA-1088), where updated safety information is posted as it becomes available.

Drug interactions:

• Medicines that affect pituitary or adrenal function, including corticosteroids, some anticonvulsants, psychotropic drugs, hormone preparations, antithyroid agents, and cyproheptadine, can alter the body’s response and may make test results unreliable, so they are often stopped before Metopirone testing when clinically possible.
• Acetaminophen (paracetamol) should be avoided with Metopirone because metyrapone can inhibit its glucuronidation, slow its elimination, and increase the risk of acetaminophen-related side effects, including liver toxicity.
• Other sedating drugs (such as some sleep aids, opioids, or alcohol) can add to Metopirone-related dizziness and drowsiness, so patients are usually advised not to drink alcohol and to be cautious with other sedatives around the time of testing.

Precautions and conditions making use unsafe or higher risk: Metopirone is contraindicated in people with established adrenal cortical insufficiency or known hypersensitivity to the drug, and it should be used with great caution in patients with suspected severe adrenal or pituitary failure, major systemic illness, or significant liver or kidney impairment, with testing often performed in a monitored setting.

Monitoring needs: For diagnostic use, clinicians monitor symptoms and measure cortisol, ACTH, and related steroid levels in blood or urine; for off-label chronic therapy, regular monitoring of cortisol, blood pressure, electrolytes, and overall clinical status is required to avoid both cortisol excess and deficiency.

Q: What is Metopirone used for?
A: In the United States, Metopirone is mainly used, together with other tests, to help doctors find out whether a person has adrenal insufficiency, and in some specialized cases it is also used off-label to help control high cortisol in Cushing’s syndrome.

Q: Will I take Metopirone every day?
A: Most people receive Metopirone as a single dose at midnight for a diagnostic test, while repeated or daily doses are reserved for select patients with Cushing’s syndrome and are managed only by endocrinology specialists.

Q: Can I drive or work after taking Metopirone?
A: Because Metopirone can cause dizziness and sleepiness, you should not drive, operate machinery, or do tasks that require full alertness until you know how you feel and any drowsiness has completely passed.

Q: Is Metopirone safe during pregnancy or breastfeeding?
A: Information in pregnancy and breastfeeding is limited, so use is generally avoided unless the potential benefit clearly outweighs the risk, and decisions are made on a case-by-case basis by specialists.

Q: What should I do if I feel very unwell after the test dose?
A: If you develop severe weakness, vomiting, dizziness, trouble breathing, or feel as though you might faint, seek emergency medical care immediately and tell providers that you recently took Metopirone for adrenal testing.

Storage: Store Metopirone capsules at room temperature (about 68–77°F or 20–25°C) in the original container, tightly closed, protected from moisture and heat, and out of the reach of children.

Disposal: If capsules remain after testing or treatment, use a pharmacy or community drug take-back program when possible, or follow pharmacist or local guidance; do not leave loose capsules in household trash where children or pets can reach them, and do not flush them unless specifically instructed.